Low molecular weight heparin in unstable coronary artery disease

Bibliography

• DAVIES MJ: The composition of coronary arteryplaques. N Engl. J. Med. (1997) 336:1312–1314.
   PubMed Web of Science ®Google Scholar
• THEROUX P, FUSTER V: Acute coronary syndromesunstable angina and non-Q-wave myocardial infarc-tion. Circulation (1998) 97:1195–1206.
   PubMed Web of Science ®Google Scholar
• CAMPBELL RW, WALLENTIN L, VERHEUGT FW et al.:Management strategies for a better outcome in unstable coronary artery disease. Clin. Cardiol. (1998) 21:2314–2219.
   Google Scholar
• FRAGMIN-DURING-INSTABILITY-IN-CORONARY-ARTERY-DISEASE-STUDY- GROUP: Low-molecular-weight heparin during instability in coronary artery disease. Lancet (1996) 347:561–568.
   PubMed Web of Science ®Google Scholar
• HAMM CW, HEESCHEN C, GOLDMANN B et al.: Benefit ofabciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl. J. Med. (1999) 340:1623–1629.
   Google Scholar
• FRISCII INVESTIGATORS: Long term low molecularmass heparin in unstable coronary artery disease. Lancet (1999) 354:701–707.
   PubMed Web of Science ®Google Scholar
• KJALKE M, MONROE D, HOFFMAN M, OLIVER J, EZBAN M,ROBERTS H: Active site-inactivated factors VIIa, Xa and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb. Haemost. (1998) 80:578–584.
   PubMed Web of Science ®Google Scholar
• MCNAMARA CA, SAREMBOCK IJ, BACHHUBER BG et al.:Thrombin and vascular smooth muscle cell prolifera-tion: implications for atherosclerosis and restenosis. Semin. Thromb. HemosL (1996) 22(2):139–144.
   PubMed Web of Science ®Google Scholar
• WALLENTIN L: Low molecular weight heparins: avaluable tool in the treatment of acute coronary syndromes. Eur. Heart J. (1996) 17(10):1470–1476.
   PubMed Web of Science ®Google Scholar
• TURPIE AGG: Clinical trials of low molecular weightheparin. Am. J. Cardiol. (1999):R18–R27.
   Google Scholar
• SAMAMA MM, BARA L, GEROTZIAFAS GT: Mechanismsfor the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis (1994) 24:105–117.
   PubMedGoogle Scholar
• TELFORD AM, WILSON C: Trial of heparin versusatenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet (1981) 1:1225–1228.
   PubMed Web of Science ®Google Scholar
• THEROUX P, OUIMET H, MCCANS J et al: Aspirin,heparin or both to treat acute unstable angina. N Engl. J. Med. (1988) 319:1105–1111.
   PubMed Web of Science ®Google Scholar
• THEROUX P, WATERS D, QIU S et al.: Aspirin versusheparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation (1993) 88:2045–2048.
   PubMed Web of Science ®Google Scholar
• RISC GROUP: Risk of myocardial infarction and deathduring treatment with low dose aspirin and intrave-nous heparin in men with unstable coronary artery disease. Lancet (1990) 336: 827–830.
   PubMed Web of Science ®Google Scholar
• HOLDRIGHT D, PATEL D, CUNNINGHAM D et al.: Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. JACC (1994) 24:39–45.
   Google Scholar
• COHEN M, ADAMS PC, PARRY G et al.: Combinationantithrombotic therapy in unstable rest angina and non-Q-Wave infarction in nonprior aspirin users. Circulation (1994) 89:81–88.
   PubMed Web of Science ®Google Scholar
• LEWIS DH, DAVIS JW, ARCHIBALD DG et al.: Protectiveeffects of aspirin against acute myocardial infarction and death inmen with unstable angina. N Engl. J. Med. (1983) 309:396–403.
   PubMed Web of Science ®Google Scholar
• CAIRNS JA, GENT M, SINGER J et al.: Aspirin, sulfinpyra-zone, or both in unstable angina: results of a Canadian multicentre trial. N Engl. J. Med. (1985) 313:1369–1375.
   PubMed Web of Science ®Google Scholar
• OLER A, WHOOLEY MA, OLER J, GRADY D: Adding heparin to aspirin reduces the incidence of myocar-dial infarction and death in patients with unstable angina. A meta-analysis. JAMA (1996) 276:811–815.
   PubMed Web of Science ®Google Scholar
• THEROUX P, WATERS D, LAM J et al.: Reactivation ofunstable angina after the discontinuation of heparin. N Engl. J. Med. (1992) 327:141–145.
   PubMed Web of Science ®Google Scholar
• THE THROMBIN INHIBITION IN MYOCARDIAL ISCHAEMIA (TRIM) STUDY GROUP: A low molecular weight, selective thrombin inhibitor, inogatran, vs. heparin, for unstable coronary artery disease in 1209 patients. Eur. Heart J. (1997) 18:1416–1425.
   Google Scholar
• GRANGER CB, HIRSCH J, CALIFF RM et al.: Activatedpartial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation (1996) 93:870–878.
   PubMed Web of Science ®Google Scholar
• US DEPARTMENT OF HEALTH AND HUMAN SERVICES:Unstable angina: diagnosis and management. Clinical practice guidelines. AHCPR Publication No 94–0602 (1994).
   Google Scholar
• KLEIN W, BUCHWALD A, HILLIS SE, MONRAD S et al.: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study. Circulation (1997) 96:61–68.
   Google Scholar
• FRAXIS TRIALISTS: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfraction-ated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. Eur. Heart J. (1999) 20:1553–1562.
   PubMed Web of Science ®Google Scholar
• COHEN M, DEMERS C, GURFINKEL EP et al.: Acomparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl. J. Med. (1997) 337:447–452.
   Google Scholar
• ANTMAN EM, MCCABE CH, GURFINKEL EP et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 100:1593–1601.
   Google Scholar
• ANTMAN EM, COHEN M, RADLEY D eta].: Assessment ofthe treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation (1999) 100:1602–1608.
   Google Scholar
• MERLINI P, BAUER K, OLTRONA L et al: Persistent activa-tion of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 90:61–68.
   PubMed Web of Science ®Google Scholar
• LINDAHL B, VENGE P, WALLENTIN L: Troponin T identi-fies patients with unstable coronary artery disease, who benefit from long-term antithrombotic protec-tion. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J. Am. Coll. Cardiol (1997) 29:43–48.
   PubMed Web of Science ®Google Scholar
• LINDAHL B, DIDERHOLM E, KONTNY F et al.: Long term treatment with low molecular weight heparin (dalteparin) reduces cardiac events in unstable coronary artery disease (UCAD) with troponin-T elevation: a FRISCII substudy. Circulation (1999) 100(1)498.
   Web of Science ®Google Scholar
• FRISCII INVESTIGATORS: Invasive compared with noninvasive treatment in unstable coronary artery disease. Lancet (1999) 354:708–715.
   PubMed Web of Science ®Google Scholar
• ANAND SS, YUSUF S, POGUE J, WEITZ JI, FLATHER M:Long-term oral anticoagulant therapy in patients with unstable angina or suspect non-q-wave myocardial infarction. Circulation (1998) 98:1064–1070.
   PubMed Web of Science ®Google Scholar
• ANAND SS, YUSUF S: Randomized trial of oral antico-agulation therapy in patients with acute ischemic syndromes without ST-elevation: importance of good compliance. J. Amer. Coll. Cardiol (1999) 33:396A.
   Google Scholar
• © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3)
   Google Scholar
• THE THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) 11A TRIAL INVESTIGATORS: Dose-ranging trial of enoxaparin for unstable angina: results of MIL 11A. J. Am. Coll. Cardiol (1997) 29:1474–1482.
   PubMed Web of Science ®Google Scholar
• TOSS H, WALLENTIN L, SIEGBAHN A: Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am. Heart J. (1999) 137:72–78.
   PubMed Web of Science ®Google Scholar
• GUSTO IIB: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl. J. Med. (1996) 335:775–782.
   PubMed Web of Science ®Google Scholar
• LINDER R, OLDGREN J, EGBERG L et al.: The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur. Heart 1 (1999) 20(7):506–518.
   Google Scholar
• DE CRISTOFARO R, DE CANDIA E, LANDOLFI R: Effect of high- and low-molecular-weight heparins on thrombin-thrombomodulin interaction and protein C activation. Circulation (1998) 98:1297–1301.
   PubMed Web of Science ®Google Scholar